Background: Approaches to treatment-experienced HIV-infected patients with persistent low-level viremia are limited by current commercial resistance genotyping assays when the viral load (VL) is <500 copies/mL. The best intervention to achieve virologic suppression in this population is unclear. Methods: This is a case control retrospective chart review study of 149 HIV-infected patients with a VL of 50 to 1000 copies/mL. Patients were in either regimen unchanged group or intervention group (intensification of regimen or switch without guidance from resistance testing). End point was VL < 100 copies/mL. Results: At 6 months post change, 30.8% of patients with intervention versus 36.6% with no intervention achieved a complete virologic suppression. There were no statistically significant differences between these 2 groups (P ¼ .254). The majority of patients without regimen change eventually progressed to complete virologic failure. Conclusion: Patients with persistent low levels of viremia are likely to progress to have virologic failure. This supports the adoption of a more proactive approach to treatment and more sensitive technique to identify drug resistance.
Introduction
Studies have suggested that persistent low-level viremia in treatment-experienced patients leads to clinically significant resistance mutations. [1] [2] [3] [4] Treatment options include leaving the current regimen unchanged until viremia reaches a level where resistance testing can be performed, treatment interruption followed by resistance testing, intensification of the current regimen, or switch to new regimen (salvage therapy) without guidance from resistance testing. To our knowledge, there have been no studies to compare which of these approaches will yield optimal HIV virologic outcome.
Methods
We designed a caseÀcontrol retrospective chart review study to look at approximately 2000 HIV-infected adults at the Hillsborough County Health Department, Tampa, Florida, from January 1, 2006 to June 30, 2007. We used Lab Tracker (a computerized database) to track serial laboratories including viral loads (VLs). Patients included in our study were on antiretroviral therapy and had at least 2 consecutive VLs above 50 and less than 1000 copies/mL. We used the SPSS version 15 for data analysis and chi-square test was used for comparison of virologic outcomes of patients who were continued on the same regimen to those of patients with changes in treatment by one of the following strategies: treatment interruption, intensification, or switch. We recorded the HIV VL at 6 months following the decision to intervene, either continue or change the existing regimen.
Results
A total of 149 patients met our inclusion criteria, of which 26 had changes in treatment (cases) and 123 had no change (control). There was no statistically significant difference in these 2 groups in terms of age, gender, ethnicity, and HIV risk factors as shown in the table above.
When regimens were changed, providers mostly switched one of the classes to another class that the patient was not exposed to in the past by history. None of the patients with intervention had treatment interruption. There were 8 (30.8%) patients in the case group compared to 45 (36.6%) patients in the control group that achieved a complete virologic suppression after 6 months of the intervention. There were no statistically significant differences between these 2 groups (P ¼ .254). There were 69 (56.1%) patients in the control group and 18 (69.2%) patients in case group that maintained viremia between the above complete virologic suppression level and VL 1000. There were 9 (7.3%) patients in the control group whose viremia rebounded to >1000 after 6 months, whereas there was no patient in the case group with virologic failure. However, the subgroup analysis among those did not have a complete virologic suppression showed the difference was not statistically significant (P ¼ .130).
Discussion
According to the current US Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescent, 1 the goal of HIV therapy has been to maintain the plasma VL below the detectable level of 50 copies/mL. This is based on the fact that maintaining the VL undetectable decreases accumulation of resistance mutations and delays progression to AIDS. 2 Moreover, persistent low-level viremia is associated with increased risk of virologic failure and mortality. 3 Most patients respond to the current highly active antiretroviral therapy (HAART) but can experience intermittent transient low-level viremia or blips. These may not lead to immunologic or virologic failure. [4] [5] [6] [7] Persistent viremia, however, suggests ongoing viral replication and treatment failure. 4, 8 Patients with VLs more than 400 copies/mL are more likely to experience sustained viral rebound and to have an impaired CD4 count rise relative to those who maintain undetectable VL. 8 Failure of treatment in such cases can be due to accumulation of viral resistance. 4 Resistance mutations can be detected commercially at a VL greater than 500 to 1000 copies/mL. When adherence is not the primary concern, clinicians have approached these patients in different ways including close observation, intensification of regimen, or change to a salvage therapy. In our study population, the majority of patients with low-level viremia were observed closely with no regimen change, and more than 70% progressed to virologic failure. With the high propensity to mutate, ongoing viral replication in the presence of therapy will ultimately result in rapid selection of drug-resistant mutation and subsequent virologic rebound. 9 In this study, patients who had intervention either by regimen intensification or by switching to salvage therapy, without drug-resistance guidance did not have statistically significant reduction in their VL compared to the observation group.
The concern with treatment intensification without prior knowledge of drug-resistance patterns has been (1) choosing the wrong drug in regard to its effectiveness in providing durable viral suppression, and (2) inducing new resistance mutations to the new class of drug in case it was the only active agent in the regimen selected.
No patient had treatment interruption during this study period. This approach is controversial, although few studies found this intervention useful, 10 it was not used by our providers.
Besides the retrospective nature of the study and the relatively small sample size, the major limitation of the study is that it was conducted prior to the advent of the newer antiretroviral drugs such as CCR5 receptor antagonist, integrase inhibitors, second-generation protease inhibitors (tipranavir and darunavir) and second-generation nonnucleoside reverse transcriptase inhibitors ([NNRTIs] etravirine). However, researchers tried to use newer antiretroviral drugs such as raltegravir or maraviroc to intensify HAART regimen in this patient population, the result has been disappointing. 11, 12 Conclusion Persistent low-level viremia is likely to lead to virologic failure. This supports the adoption of a more proactive approach to treatment. The best approach for treatment seems to depend on selection of drugs based on knowledge of viral resistance mutations. There is a need to develop commercially ultrasensitive genotypic assays and to develop new therapeutic modalities like targeting HIV reservoirs.
